Eli Lilly is entering a new era of corporate expansion, utilizing the massive financial windfall from its blockbuster GLP-1 weight-loss medications, Mounjaro and Zepbound, to aggressively pursue a broader range of acquisitions. Jacob Van Naarden, who now leads both the company’s oncology division and its corporate development efforts, indicated that the pharmaceutical giant is no […]